

# Febrile Neutropenia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/F8617FF6C838EN.html>

Date: May 2024

Pages: 131

Price: US\$ 6,499.00 (Single User License)

ID: F8617FF6C838EN

## Abstracts

The 7 major febrile neutropenia markets reached a value of US\$ 10.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 16.3 Billion by 2034, exhibiting a growth rate (CAGR) of 4.15% during 2024-2034.

The febrile neutropenia market has been comprehensively analyzed in IMARC's new report titled "Febrile Neutropenia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Febrile neutropenia is a medical condition characterized by the presence of a fever (body temperature above 38.3°C or 101°F) in a patient with low neutrophil counts. This disease can affect the body's ability to fight infections, increasing the likelihood of health complications, such as severe sepsis and septic shock. The common indications of the ailment include unexplained fever, general weakness, tiredness, episodes of chills and sweating, increased heart rate, sore throat, difficulty swallowing, painful mouth sores, coughing, shortness of breath, chest and abdominal pain, nausea, vomiting, diarrhea, etc. The diagnosis of febrile neutropenia is mainly based on the patient's symptoms, medical history, and physical examination findings. Blood cultures and a complete blood count test are also utilized to detect the presence of bacteria or fungi in the bloodstream and identify other abnormalities. The healthcare provider may further perform numerous imaging studies, such as a chest X-ray, a computed tomography (CT) scan, an ultrasound, etc., to identify the source of infection and rule out other possible causes of indications among patients.

The increasing utilization of chemotherapy or radiation therapy, which can suppress the bone marrow's ability to produce new blood cells, is primarily driving the febrile neutropenia market. In addition to this, the rising incidences of various associated risk

factors, including nutritional deficiencies, kidney diseases, usage of certain medications, like corticosteroids, that can affect immune function, etc., are also bolstering the market growth. Furthermore, the inflating adoption of broad-spectrum antibiotics to control the infection while providing coverage against a wide array of other potential pathogens is creating a positive outlook for the market. Besides this, the escalating application of colony-stimulating factors, such as filgrastim and pegfilgrastim, to treat the underlying symptoms of the ailment is also propelling the market growth. These medications work by stimulating the production of white blood cells, specifically neutrophils, to accelerate the recovery of the immune system. Additionally, the emerging popularity of intravenous antifungal therapy for treating the condition in patients who are unresponsive to other conventional antibiotic regimens is expected to drive the febrile neutropenia market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the febrile neutropenia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for febrile neutropenia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the febrile neutropenia market in any manner.

### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

### Countries Covered

United States

Germany

France

United Kingdom

Italy  
Spain  
Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the febrile neutropenia market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the febrile neutropenia market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current febrile neutropenia marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the febrile neutropenia market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the febrile neutropenia market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the febrile neutropenia market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (2018-2034) of febrile neutropenia across the seven major markets?

What is the number of prevalent cases (2018-2034) of febrile neutropenia by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of febrile neutropenia by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with febrile neutropenia across the seven major markets?

What is the size of the febrile neutropenia patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of febrile neutropenia?

What will be the growth rate of patients across the seven major markets?

### Febrile Neutropenia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for febrile neutropenia drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc.

related to the febrile neutropenia market?

What are the key regulatory events related to the febrile neutropenia market?

What is the structure of clinical trial landscape by status related to the febrile neutropenia market?

What is the structure of clinical trial landscape by phase related to the febrile neutropenia market?

What is the structure of clinical trial landscape by route of administration related to the febrile neutropenia market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 FEBRILE NEUTROPENIA - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 FEBRILE NEUTROPENIA - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 FEBRILE NEUTROPENIA - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (2018-2034)
  - 7.2.4 Epidemiology by Gender (2018-2034)
  - 7.2.5 Diagnosed Cases (2018-2034)
  - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (2018-2034)
  - 7.3.4 Epidemiology by Gender (2018-2034)
  - 7.3.5 Diagnosed Cases (2018-2034)
  - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (2018-2034)
  - 7.4.4 Epidemiology by Gender (2018-2034)
  - 7.4.5 Diagnosed Cases (2018-2034)
  - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (2018-2034)
  - 7.5.4 Epidemiology by Gender (2018-2034)
  - 7.5.5 Diagnosed Cases (2018-2034)
  - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (2018-2034)
  - 7.6.4 Epidemiology by Gender (2018-2034)
  - 7.6.5 Diagnosed Cases (2018-2034)
  - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (2018-2034)
  - 7.8.4 Epidemiology by Gender (2018-2034)
  - 7.8.5 Diagnosed Cases (2018-2034)
  - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (2018-2034)
  - 7.9.4 Epidemiology by Gender (2018-2034)
  - 7.9.5 Diagnosed Cases (2018-2034)
  - 7.9.6 Patient Pool/Treated Cases (2018-2034)

## **8 FEBRILE NEUTROPENIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 FEBRILE NEUTROPENIA - UNMET NEEDS**

## **10 FEBRILE NEUTROPENIA - KEY ENDPOINTS OF TREATMENT**

## **11 FEBRILE NEUTROPENIA - MARKETED PRODUCTS**

- 11.1 List of Febrile Neutropenia Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Neupogen (Filgrastim) - Amgen/Roche
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets
  - 11.1.2 Rovedon (Eflapegrastim) - Hanmi Pharmaceutical/Spectrum Pharmaceuticals
    - 11.1.2.1 Drug Overview



- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets
- 11.1.3 Neulasta (Pegfilgrastim) - Amgen/Kyowa Kirin
  - 11.1.3.1 Drug Overview
  - 11.1.3.2 Mechanism of Action
  - 11.1.3.3 Regulatory Status
  - 11.1.3.4 Clinical Trial Results
  - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Maxipime (Cefepime) - Bristol-Myers Squibb
  - 11.1.4.1 Drug Overview
  - 11.1.4.2 Mechanism of Action
  - 11.1.4.3 Regulatory Status
  - 11.1.4.4 Clinical Trial Results
  - 11.1.4.5 Sales Across Major Markets
- 11.1.5 AmBisome (Amphotericin B liposomal) - Gilead Sciences
  - 11.1.5.1 Drug Overview
  - 11.1.5.2 Mechanism of Action
  - 11.1.5.3 Regulatory Status
  - 11.1.5.4 Clinical Trial Results
  - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

## **12 FEBRILE NEUTROPENIA - PIPELINE DRUGS**

- 12.1 List of Febrile Neutropenia Pipeline Drugs Across the Top 7 Markets
  - 12.1.1 MD 110 - Mochida Pharmaceutical
    - 12.1.1.1 Drug Overview
    - 12.1.1.2 Mechanism of Action
    - 12.1.1.3 Clinical Trial Results
    - 12.1.1.4 Safety and Efficacy
    - 12.1.1.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

## **13. FEBRILE NEUTROPENIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. FEBRILE NEUTROPENIA – CLINICAL TRIAL LANDSCAPE**

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

## **15 FEBRILE NEUTROPENIA - MARKET SCENARIO**

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
  - 15.2.1 Febrile Neutropenia - Market Size
    - 15.2.1.1 Market Size (2018-2023)
    - 15.2.1.2 Market Forecast (2024-2034)
  - 15.2.2 Febrile Neutropenia - Market Size by Therapies
    - 15.2.2.1 Market Size by Therapies (2018-2023)
    - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
  - 15.3.1 Febrile Neutropenia - Market Size
    - 15.3.1.1 Market Size (2018-2023)
    - 15.3.1.2 Market Forecast (2024-2034)
  - 15.3.2 Febrile Neutropenia - Market Size by Therapies
    - 15.3.2.1 Market Size by Therapies (2018-2023)
    - 15.3.2.2 Market Forecast by Therapies (2024-2034)
  - 15.3.3 Febrile Neutropenia - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
  - 15.4.1 Febrile Neutropenia - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (2024-2034)
  - 15.4.2 Febrile Neutropenia - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (2024-2034)
  - 15.4.3 Febrile Neutropenia - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Febrile Neutropenia - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Febrile Neutropenia - Market Size by Therapies

- 15.5.2.1 Market Size by Therapies (2018-2023)
- 15.5.2.2 Market Forecast by Therapies (2024-2034)
- 15.5.3 Febrile Neutropenia - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Febrile Neutropenia - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Febrile Neutropenia - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Febrile Neutropenia - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Febrile Neutropenia - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Febrile Neutropenia - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034)
  - 15.7.3 Febrile Neutropenia - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Febrile Neutropenia - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034)
  - 15.8.2 Febrile Neutropenia - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2018-2023)
    - 15.8.2.2 Market Forecast by Therapies (2024-2034)
  - 15.8.3 Febrile Neutropenia - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Febrile Neutropenia - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Febrile Neutropenia - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Febrile Neutropenia - Access and Reimbursement Overview

## **16 FEBRILE NEUTROPENIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 FEBRILE NEUTROPENIA MARKET - SWOT ANALYSIS**

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

## **18 FEBRILE NEUTROPENIA MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Febrile Neutropenia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/F8617FF6C838EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/F8617FF6C838EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

